Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2001 by S. Karger AG,
P.O. Box, CH-4009 Basel (Switzerland)
Printed in Switzerland on acid-free paper by
Reinhardt Druck, Basel
ISBN 3-8055-7177-1
Contents

VII Preface

Main Papers

1 Genetic Heterogeneity in Hereditary Thrombophilia
   Reitsma, P.H. (Amsterdam)

11 Aspects of the Clinical Management of Hereditary Thrombophilia: A Personal Perspective
   Mannucci, P.M. (Milan)

16 Antiphospholipid Syndrome: State of the Art with Emphasis on Laboratory Evaluation
   Greaves, M. (Aberdeen)

26 Causes of Thrombophilia Yet to Be Discovered: A Personal View
   Griffin, J.H.; Deguchi, H.; Fernandez, J.A. (La Jolla, Calif.)

34 Does Inflammation Contribute to Thrombotic Events?
   Esmon, C.T. (Oklahoma City, Okla.)

41 Cellular Consequences upon Factor VIIa Binding to Tissue Factor
   Siegbahn, A. (Uppsala)

48 Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins
   Sandset, P.M.; Bendz, B.; Hansen, J.-B. (Oslo)

57 Which Antiphospholipid Antibodies Should Be Measured in the Antiphospholipid Syndrome?
   Galli, M. (Bergamo)
Workshop 1  Chairman: A.S. Gallus
Risk Assessment and Prophylaxis of Venous
Thromboembolism in Non-Surgical Patients

63 Chairman’s Comments
Gallus, A.S. (Bedford Park)

64 Preventing Venous Thromboembolism in General Medical
Inpatients and after an Ischaemic Stroke
Gallus, A.S. (Bedford Park)

72 Risk Assessment and Prophylaxis of Venous
Thromboembolism in Non-Surgical Patients: Cancer as a
Risk Factor
Otten, H.-M.M.B.; Prins, M.H.; Smorenburg, S.M.; Hutten, B.A.
(Amsterdam)

77 Risk Assessment and Prophylaxis of Venous
Thromboembolism in Acutely and/or Critically Ill Patients
Davidson, B.L. (Seattle, Wash.)

Workshop 2  Chairman: S.P. Frostick
Thromboprophylaxis after Hip and Knee Replacement:
6 Days or 3 Months?

82 Chairman’s Comments
Frostick, S.P. (Liverpool)

84 Death after Joint Replacement
Frostick, S.P. (Liverpool)

88 Extended Thromboprophylaxis following Lower Limb
Arthroplasty: What Do the Clinical Trials Mean?

95 New Insights into Extended Prophylaxis after Orthopaedic
Surgery - the North American Fragmin Trial Experience
Hull, R.D. (Calgary)

101 Continuing Out-of-Hospital Prophylaxis following Major
Orthopaedic Surgery: What Now?
Dahl, O.E. (Oslo)
Workshop 3  Chairman: L. Wallentin
Is Low-Molecular-Weight Heparin Part of Optimal Therapy in Unstable Coronary Artery Disease?

106 Chairman’s Comments
Wallentin, L. (Uppsala)

108 Low-Molecular-Weight Heparin as a Bridge to Timely Revascularization in Unstable Coronary Artery Disease – an Update of the Fragmin during Instability in Coronary Artery Disease II Trial
Wallentin, L. (Uppsala)

114 Low-Molecular-Weight Heparin and Other Antithrombotic Agents in the Setting of a Fast-Track Revascularization in Unstable Coronary Artery Disease
Bassand, J.-P. (Besançon)

122 Low-Molecular-Weight Heparin and Other Antithrombotic Agents in the Setting of a Primarily Medical Treatment of Unstable Coronary Artery Disease
Verheugt, F.W.A. (Nijmegen)

Workshop 4  Chairman: D. Bergqvist
Health Economy Aspects on the Use of Low-Molecular-Weight Heparins

128 Chairman’s Comments
Bergqvist, D. (Uppsala)

130 Cost-Effectiveness of Prolonged Out-of-Hospital Prophylaxis with Low-Molecular-Weight Heparin following Total Hip Replacement
Bergqvist, D. (Uppsala); Jönsson, B. (Stockholm)

136 Does Low-Molecular-Weight Heparin Reduce the Costs of Venous Thromboembolism Treatment?
Bossuyt, P.M.M.; Prins, M.H. (Amsterdam)

141 Thromboprophylaxis with Low-Molecular-Weight Heparin: Economic Considerations
Mätzsch, T. (Malmö)
Plenary Debate

Chairman: V.J. Marder

Are Low-Molecular-Weight Heparins Interchangeable?

146 Chairman’s Comments
Marder, V.J. (Los Angeles, Calif.)

148 Low-Molecular-Weight Heparins: Are They Interchangeable?
van der Heijden, J.F.; Prins, M.H.; Büller, H.R. (Amsterdam)

158 Low-Molecular-Weight Heparins in the Management of Unstable Angina
Agnelli, G.; Sonaglia, F. (Perugia)

Posters

168 Improvement of Outcome in Patients with Acute Ischaemic Stroke Treated with Fragmin
Dan, G.-A.; Gonta, A.; Serbanescu, A.; Ionete, C. (Bucharest)

170 Dalteparin, a Low-Molecular-Weight Heparin, Reduces Ischaemia/Reperfusion-Induced Liver Injury in Rats by Increasing the Hepatic Level of Prostacyclin
Okajima, K. (Kumamoto); Harada, N. (Fukuoka); Uchiba, M. (Kumamoto)

172 The Prothrombinase-Induced Clotting Test: A New Technique for the Monitoring of Anticoagulants
Calatzis, A.; Spannnagl, M. (Munich); Gempeler-Messina, P.; Kolde, H.J. (Basel); Schramm, W.; Haas, S. (Munich)

175 Conclusion
Haas, S. (Munich); Marder, V.J. (Los Angeles, Calif.); Samama, M.-M. (Paris)

177 Author Index
178 Subject Index